Trial Profile
An efficacy trial of Intensive Fir-B/Fox Triplet Chemotherapy plus Bevacizumab in Patients with Metastatic Colorectal Cancer assessing Kras Genotype and the Prevalent C.35 G > A Mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 Dec 2015 New trial record